- Home
- IGR vs IMTX Comparison
IGR vs IMTX Comparison
Compare IGR & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGR
- IMTX
- Stock Information
- Founded
- IGR 2004
- IMTX N/A
- Country
- IGR United States
- IMTX Germany
- Employees
- IGR N/A
- IMTX N/A
- Industry
- IGR Finance Companies
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IGR Finance
- IMTX Health Care
- Exchange
- IGR Nasdaq
- IMTX Nasdaq
- Market Cap
- IGR 752.8M
- IMTX 653.9M
- IPO Year
- IGR N/A
- IMTX N/A
- Fundamental
- Price
- IGR $4.92
- IMTX $6.33
- Analyst Decision
- IGR
- IMTX Strong Buy
- Analyst Count
- IGR 0
- IMTX 4
- Target Price
- IGR N/A
- IMTX $14.67
- AVG Volume (30 Days)
- IGR 747.7K
- IMTX 537.7K
- Earning Date
- IGR 01-01-0001
- IMTX 08-13-2025
- Dividend Yield
- IGR 13.93%
- IMTX N/A
- EPS Growth
- IGR N/A
- IMTX N/A
- EPS
- IGR N/A
- IMTX N/A
- Revenue
- IGR N/A
- IMTX $152,823,253.00
- Revenue This Year
- IGR N/A
- IMTX N/A
- Revenue Next Year
- IGR N/A
- IMTX $1.92
- P/E Ratio
- IGR N/A
- IMTX N/A
- Revenue Growth
- IGR N/A
- IMTX 83.61
- 52 Week Low
- IGR $3.88
- IMTX $3.30
- 52 Week High
- IGR $5.70
- IMTX $13.09
- Technical
- Relative Strength Index (RSI)
- IGR 43.69
- IMTX 52.73
- Support Level
- IGR $4.80
- IMTX $5.56
- Resistance Level
- IGR $4.94
- IMTX $6.50
- Average True Range (ATR)
- IGR 0.07
- IMTX 0.35
- MACD
- IGR 0.01
- IMTX -0.07
- Stochastic Oscillator
- IGR 72.50
- IMTX 62.10
About IGR CBRE Global Real Estate Income Fund of Beneficial Interest
CBRE Clarion Global Real Estate Income Fund is a United States-based diversified, closed-end management investment company. Its primary objective is high current income, and its secondary objective is capital appreciation. The fund invests a majority of its total assets in income-producing real estate securities, which includes common stocks, preferred securities, warrants, and convertible securities issued by real estate companies, such as real estate investment trusts. Under normal market conditions, it invests in real estate equity securities of companies domiciled predominantly in developed countries.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.